Sareum Holdings (LSE:SAR) Short-Term Debt : £0.00 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Sareum Holdings Short-Term Debt?

Sareum Holdings's Short-Term Debt for the quarter that ended in Dec. 2023 was £0.00 Mil.

Sareum Holdings Short-Term Debt Historical Data

The historical data trend for Sareum Holdings's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sareum Holdings Short-Term Debt Chart

Sareum Holdings Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Short-Term Debt

Get a 7-Day Free Trial

Sareum Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Sareum Holdings Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Sareum Holdings Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Sareum Holdings's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Sareum Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sareum Holdings PLC (LSE:SAR) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

RYH0:Germany

Address

Langford Arch, London Road, Unit 2a, Pampisford, Cambridge, Cambridgeshire, GBR, CB22 3FX

Website

http://www.sareum.com

Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.